Eisai to Present Data on Oncology Pipeline and Products at ASCO Annual Meeting
Eisai to Present Data on Oncology Pipeline and Products at ASCO Annual Meeting

TOKYO, May 20, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that the latest data regarding its oncology pipeline and products including in-house discovered lenvatinib mesylate (multikinase inhibitor, product name: LENVIMA, “lenvatinib”) and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN, “eribulin”) will be presented at the American Society... » read more

Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab
Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab

TOKYO, Mar 30, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that the European Medicines Agency (EMA) has confirmed it has accepted for review applications for the use of its in-house discovered multiple receptor tyrosine kinase inhibitor, lenvatinib mesylate (product name: LENVIMA / Kisplyx, “lenvatinib”), in combination with anti-PD-1 therapy pembrolizumab... » read more